NKMAX, Subsidiary Receives US Securities and Exchange Commission Listing Approval

NKMax's subsidiary NKGen Biotech has received approval for listing from the U.S. Securities and Exchange Commission (SEC).

NKGen Biotech and the special purpose acquisition company (SPAC) Graf Acquisition Corp. IV (hereinafter Graf) announced on the 16th that the S-4 registration statement became effective as of the 14th by the U.S. SEC. The two companies plan to hold a special shareholders' meeting in New York on the 30th to approve the merger.

It is reported that Graf began mailing proxy statements and information regarding the merger to shareholders registered in the shareholder registry as of the 14th. These recipients will be able to exercise their voting rights at the shareholders' meeting.

Additionally, Graf announced plans to transfer its listing from the New York Stock Exchange (NYSE) to Nasdaq after the merger is completed. If the merger is successfully completed, Graf will change its name to NKGen Biotech, Inc. and begin trading on Nasdaq under the ticker symbol 'NKGN'.

NKGen Biotech stated, "The Nasdaq listing is a decision made considering the merger, aiming to stand shoulder to shoulder with many innovative life sciences companies listed on Nasdaq."

This content was produced with the assistance of AI translation services.